In this trial, PD-L1+ status was characterized by patient PD-L1 combined positive scores (CPS), defined as the ratio of PD-L1+ tumor cells, lymphocytes, and macrophages out of total tumor cells multiplied by 100. This evidence concerns the gene CD274 and neoplasm.